Glucosio Con Sodio Cloruro Iii Bioindustria L.I.M.

Glucosio Con Sodio Cloruro Iii Bioindustria L.I.M. is an intravenous injection solution that contains sodium chloride and glucose monohydrate. The preparation is supplied as a sterile liquid for infusion, intended for use in the European Union market. It provides both an electrolyte (sodium) and a carbohydrate source (glucose) to support fluid balance and energy needs in clinical settings. The product is prescription‑only and is administered under medical supervision.

Glucosio Con Sodio Cloruro Iii is indicated for several clinical situations where fluid, electrolyte, and carbohydrate replacement are required.

- Fluid replacement in patients with dehydration or blood loss. - Maintenance of electrolyte balance during surgery or critical illness. - Treatment of hypoglycemia when rapid glucose administration is needed. - Pre‑operative and peri‑operative hydration to support hemodynamic stability. - Management of electrolyte disturbances such as hyponatremia. - Support of energy metabolism during prolonged fasting or catabolic states. - The solution can be administered intravenously as a bolus or continuous infusion, depending on the clinical need.

Adverse reactions to Glucosio Con Sodio Cloruro Iii are generally related to the intravenous administration of electrolytes and glucose.

Common: - Mild injection site discomfort or erythema. - Transient hyperglycemia, especially in patients with impaired glucose tolerance. - Slight increase in serum sodium leading to mild hypernatremia. - Nausea or vomiting shortly after infusion. - Transient headache or dizziness during infusion. - Mild metabolic acidosis in patients receiving large volumes.

Serious: - Severe hypernatremia causing neurologic symptoms. - Acute hyperglycemia with osmotic diuresis. - Allergic reaction such as urticaria, bronchospasm, or anaphylaxis. - Fluid overload resulting in pulmonary edema. - Electrolyte imbalance leading to cardiac arrhythmias. - These events are usually dose‑dependent and may be mitigated by appropriate monitoring.

When using Glucosio Con Sodio Cloruro Iii, clinicians should observe specific precautions to ensure patient safety and optimal therapeutic effect.

- Assess serum electrolytes and glucose before administration. - Adjust infusion rate in patients with renal or cardiac impairment. - Avoid rapid bolus in individuals at risk for fluid overload. - Monitor blood glucose during and after infusion, especially in diabetic patients. - Use caution in neonates and elderly due to altered fluid distribution. - Ensure compatibility with other IV solutions before mixing. - Document any adverse reactions promptly.

Glucosio Con Sodio Cloruro Iii may interact with other medications administered intravenously or affecting fluid and electrolyte balance.

Avoid: - Co‑administration with hypertonic saline solutions, which can cause excessive sodium load. - Simultaneous infusion of high‑dose dextrose solutions that may lead to severe hyperglycemia. - Concurrent use with potassium chloride infusions, which may cause hyperkalemia.

Use with caution: - Loop diuretics, as they can exacerbate electrolyte shifts. - Insulin therapy, requiring close monitoring of blood glucose. - Cardiac glycosides, because altered electrolyte levels may affect drug efficacy. - Blood products, to prevent incompatibility and precipitation. - Vasopressors, as rapid volume changes can influence hemodynamic response.